Nagi Bioscience aims to revolutionize the way toxic and/or beneficial effects of substances are tested.
Nagi Bioscience has raised $13.6M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
Nagi Bioscience's investors include Verve Ventures, imec.xpand, European Innovation Council, MassChallenge, Zúrcher Kantonal Bank.
Nagi Bioscience is headquartered in Lausanne, Switzerland.
Nagi Bioscience aims to revolutionize the way toxic and/or beneficial effects of substances are tested.
Nagi Bioscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nagi Bioscience — Funding & Investors." VCBacked, September 28, 2023, https://www.vcbacked.co/company/nagi-bioscience. Accessed September 2, 2026.
VCBacked. (2023). Nagi Bioscience — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/nagi-bioscience
{{cite web |title=Nagi Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/nagi-bioscience |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated